Novartis (NVS) Projected to Post Quarterly Earnings on Wednesday

Novartis (NYSE:NVS) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Novartis to post earnings of $1.97 per share and revenue of $13.8502 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 4, 2026 at 1:00 AM ET.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). Novartis had a net margin of 26.49% and a return on equity of 41.21%. The firm had revenue of $14.36 billion during the quarter, compared to analysts’ expectations of $13.70 billion. During the same quarter last year, the firm earned $2.06 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Trading Up 2.0%

Shares of NYSE:NVS opened at $152.08 on Wednesday. Novartis has a 52-week low of $97.71 and a 52-week high of $152.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.68 and a current ratio of 0.88. The company has a market cap of $321.27 billion, a P/E ratio of 20.78, a P/E/G ratio of 1.94 and a beta of 0.51. The stock’s 50-day moving average is $137.06 and its 200-day moving average is $129.08.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVS. HC Wainwright lowered shares of Novartis to a “neutral” rating in a research report on Monday, October 27th. JPMorgan Chase & Co. upgraded shares of Novartis from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research note on Monday, December 29th. TD Cowen restated a “hold” rating on shares of Novartis in a report on Monday, November 10th. Finally, Cfra Research upgraded shares of Novartis to a “hold” rating in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Novartis has an average rating of “Hold” and an average price target of $119.75.

Institutional Investors Weigh In On Novartis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Novartis by 1.7% in the third quarter. Bank of America Corp DE now owns 4,605,878 shares of the company’s stock valued at $590,658,000 after acquiring an additional 78,390 shares during the period. Northern Trust Corp boosted its holdings in Novartis by 7.7% during the 3rd quarter. Northern Trust Corp now owns 2,371,389 shares of the company’s stock valued at $304,107,000 after acquiring an additional 168,573 shares during the period. Raymond James Financial Inc. increased its position in shares of Novartis by 77.7% in the third quarter. Raymond James Financial Inc. now owns 1,648,174 shares of the company’s stock valued at $211,362,000 after acquiring an additional 720,860 shares during the period. UBS Group AG raised its holdings in shares of Novartis by 15.1% during the third quarter. UBS Group AG now owns 1,602,133 shares of the company’s stock valued at $205,458,000 after acquiring an additional 210,207 shares in the last quarter. Finally, State Street Corp raised its stake in Novartis by 0.8% in the second quarter. State Street Corp now owns 1,597,830 shares of the company’s stock worth $195,552,000 after buying an additional 12,345 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.